T6367

Abacavir sulfate (Ziagen) , a nucleoside analogue, effectively utilize its antiviral activity

HPK1-IN-9 is a potent HPK1 inhibitor. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and is a member of the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has potential for HPK1-related diseases.

Anticancer agent 60 showed anti-proliferative effect on human HepG2 cells with an IC50 value of 4.13 μM. Anticancer agent 60 exhibited anti-tumor activity in a human HepG2 xenograft mouse model.

RyRs activator 2 is a potent activator of ranibulin receptors (RyRs). ryRs activator 2 has a larvicidal activity of 30%, which is comparable to chlorfenvinphos (30%) and better than cyanobenzamide (10%).

Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN), effectively inhibiting influenza viruses with low cytotoxicity, good in vivo pharmacokinetic and pharmacodynamic properties, and good hepatic microsomal stability. It has shown investigational potential against viral infections, including influenza A, B, and C.

Imlunestrant (LY-3484356) is an orally active, selective estrogen receptor degrader that persistently inhibits ER-dependent gene transcription and cell growth. It is suitable for investigating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

ER degrader 1 is a potent degrader of the estrogen receptor (ER) with potential applications in cancer treatment, as it targets the estrogen signaling system, which is crucial for cell growth, differentiation, and apoptosis.

Bcl-2-IN-6 is a potent inhibitor of Bcl-2 (b-cell lymphoma-2) that downregulates Bcl-2 expression and increases the expression of p53, Bax, and caspase-7 mRNA. bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. bcl-2-IN-7 acts on MCF-7 cells ( Bcl2-IN-7 showed good antitumor effects on MCF-7 cells (IC50: 20.91 μM), LoVo cells (IC50: 22.30 μM), HepG2 cells (IC50: 42.29 μM) and A549 cells (IC50: 48.00 μM).

HIV-1 inhibitor-13 is an orally active HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an IC50 value of 0.14 μM against HIV-1 RT. HIV-1 inhibitor-13 is active against HIV-1 resistant strains (EC50: 2.85-18.0 nM).

RORγt modulator 2 is a modulator of retinol-related orphan receptor γt (RORyt) (IC50<50 nM) and can be used in the study of RORγt-mediated diseases such as pain, inflammation, asthma, rheumatoid arthritis, COPD, multiple sclerosis, psoriasis, colitis, neurodegenerative diseases and cancer.

SARS-CoV-2 3CLpro-IN-3, a SARS-CoV-2 3CLpro inhibitor, demonstrates antiviral, antibacterial, and antifungal properties.